Logo image of BLND

BLEND LABS INC-A (BLND) Stock Fundamental Analysis

USA - NYSE:BLND - US09352U1088 - Common Stock

3.27 USD
0 (0%)
Last: 10/16/2025, 6:32:33 PM
3.27 USD
0 (0%)
After Hours: 10/16/2025, 6:32:33 PM
Fundamental Rating

3

Taking everything into account, BLND scores 3 out of 10 in our fundamental rating. BLND was compared to 282 industry peers in the Software industry. The financial health of BLND is average, but there are quite some concerns on its profitability. BLND is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BLND was profitable.
BLND had a positive operating cash flow in the past year.
BLND had negative earnings in each of the past 5 years.
BLND had a negative operating cash flow in each of the past 5 years.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -22.10%, BLND is doing worse than 72.69% of the companies in the same industry.
BLND's Return On Equity of -31.69% is on the low side compared to the rest of the industry. BLND is outperformed by 62.41% of its industry peers.
Industry RankSector Rank
ROA -22.1%
ROE -31.69%
ROIC N/A
ROA(3y)-100.49%
ROA(5y)-70.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

BLND has a Gross Margin (64.18%) which is comparable to the rest of the industry.
BLND's Gross Margin has declined in the last couple of years.
BLND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLND has more shares outstanding
The number of shares outstanding for BLND has been increased compared to 5 years ago.
BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.62, we must say that BLND is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.62, BLND is not doing good in the industry: 74.82% of the companies in the same industry are doing better.
BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.62
ROIC/WACCN/A
WACC11.39%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.40 indicates that BLND has no problem at all paying its short term obligations.
BLND has a Current ratio of 2.40. This is in the better half of the industry: BLND outperforms 69.50% of its industry peers.
A Quick Ratio of 2.40 indicates that BLND has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.40, BLND is doing good in the industry, outperforming 69.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.85%, which is quite impressive.
Looking at the last year, BLND shows a decrease in Revenue. The Revenue has decreased by -4.76% in the last year.
The Revenue has been growing by 26.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-4.76%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-22.13%

3.2 Future

BLND is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.69% yearly.
The Revenue is expected to grow by 7.18% on average over the next years.
EPS Next Y147.81%
EPS Next 2Y79.56%
EPS Next 3Y59.69%
EPS Next 5YN/A
Revenue Next Year-22.47%
Revenue Next 2Y-0.77%
Revenue Next 3Y7.18%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 327.00 indicates a quite expensive valuation of BLND.
The rest of the industry has a similar Price/Earnings ratio as BLND.
The average S&P500 Price/Earnings ratio is at 27.31. BLND is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 33.39, the valuation of BLND can be described as expensive.
BLND's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of BLND to the average of the S&P500 Index (22.85), we can say BLND is valued slightly more expensively.
Industry RankSector Rank
PE 327
Fwd PE 33.39
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLND does not grow enough to justify the current Price/Earnings ratio.
BLND's earnings are expected to grow with 59.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.21
PEG (5Y)N/A
EPS Next 2Y79.56%
EPS Next 3Y59.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLND!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLEND LABS INC-A

NYSE:BLND (10/16/2025, 6:32:33 PM)

After market: 3.27 0 (0%)

3.27

0 (0%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners64.79%
Inst Owner Change0%
Ins Owners3.51%
Ins Owner Change2.29%
Market Cap847.98M
Analysts80
Price Target4.95 (51.38%)
Short Float %6.19%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)61.27%
Min EPS beat(2)-100%
Max EPS beat(2)222.55%
EPS beat(4)2
Avg EPS beat(4)30.64%
Min EPS beat(4)-100%
Max EPS beat(4)222.55%
EPS beat(8)5
Avg EPS beat(8)24.96%
EPS beat(12)7
Avg EPS beat(12)17.77%
EPS beat(16)10
Avg EPS beat(16)12.75%
Revenue beat(2)0
Avg Revenue beat(2)-16.94%
Min Revenue beat(2)-30.67%
Max Revenue beat(2)-3.21%
Revenue beat(4)1
Avg Revenue beat(4)-7.52%
Min Revenue beat(4)-30.67%
Max Revenue beat(4)5.71%
Revenue beat(8)2
Avg Revenue beat(8)-4.31%
Revenue beat(12)5
Avg Revenue beat(12)-1.46%
Revenue beat(16)8
Avg Revenue beat(16)0.02%
PT rev (1m)0%
PT rev (3m)-3.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)25%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.86%
Valuation
Industry RankSector Rank
PE 327
Fwd PE 33.39
P/S 5.85
P/FCF N/A
P/OCF 73.66
P/B 6.64
P/tB 6.65
EV/EBITDA N/A
EPS(TTM)0.01
EY0.31%
EPS(NY)0.1
Fwd EY2.99%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.04
OCFY1.36%
SpS0.56
BVpS0.49
TBVpS0.49
PEG (NY)2.21
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.1%
ROE -31.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.18%
FCFM N/A
ROA(3y)-100.49%
ROA(5y)-70.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
F-Score6
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 647.38%
Cap/Sales 9.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z -0.62
F-Score6
WACC11.39%
ROIC/WACCN/A
Cap/Depr(3y)157.7%
Cap/Depr(5y)104.5%
Cap/Sales(3y)2.44%
Cap/Sales(5y)1.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y147.81%
EPS Next 2Y79.56%
EPS Next 3Y59.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.76%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-22.13%
Revenue Next Year-22.47%
Revenue Next 2Y-0.77%
Revenue Next 3Y7.18%
Revenue Next 5YN/A
EBIT growth 1Y75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.59%
EBIT Next 3Y78.78%
EBIT Next 5YN/A
FCF growth 1Y98.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.44%
OCF growth 3YN/A
OCF growth 5YN/A